deltatrials
Completed PHASE2 NCT00128245

Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca

A 24-week Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled Evaluation of the Safety and Efficacy of 0.3% and 1% Pimecrolimus Ophthalmic Suspensions Used Twice Daily in Patients With Moderate to Severe Keratoconjunctivitis Sicca

Sponsor: Novartis

Conditions Keratoconjunctivitis Sicca
Interventions Pimecrolimus Vehicle
Updated 6 times since 2017 Last updated: May 22, 2020 Started: Sep 30, 2004 Primary completion: Dec 31, 2006 Completion: Dec 31, 2006

A PHASE2 clinical study on Keratoconjunctivitis Sicca, this trial is completed. The trial is conducted by Novartis and has accumulated 6 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2020 — Jan 2021 [monthly]

    Completed PHASE2

    Phase: NA → PHASE2

  5. Jun 2018 — Jun 2020 [monthly]

    Completed NA

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed NA

    First recorded

Sep 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • East Hanover, United States